Name | NT113 |
---|---|
Synonyms | NT-113 |
Description | NT-113 is an irreversible pan-ERBB inhibitor, with IC50s of 0.4, 4.35, 4.18 and 2.08 nM for EGFR, EGFRT790M, ERBB2/HER2 and ERBB4/HER4, respectively, exhibiting anti-glioma activities. |
---|---|
Related Catalog | |
Target |
EGFR:0.4 nM (IC50) ErbB2:4.18 nM (IC50) ErbB4:2.08 nM (IC50) EGFRT790M:4.35 nM (IC50) |
In Vitro | NT113 shows inhibitory activity against U87vIII cells, with IC50 of 0.19 μM[1]. |
In Vivo | NT113 (20 mg/kg/day) shows inhibitory activity against intracranial EGFRvIII-amplified GBM39 xenograft tumors. NT113 (10 mg/kg/day) causes growth delay in the U87vIII intracranial xenografts. Mice receiving NT113 treatment survive significantly longer than mice receiving lapatinib[1]. |
Cell Assay | Cells are seeded in 96 well plates: 2000 cells/well in 200 μL, in hextuplicate. One day after seeding, 1 μL of DMSO, with or without NT113, is added to cells to achieve NT113 concentrations between 0.01 and 20.0 μM. Seventy-two hours later, WST-1 reagent is added, and sample 450 nm absorbance determined using a microplate reader, with background reading at 800 nm subtracted. |
Animal Admin | Mice with intracranial GBM12 tumors are administered NT113, at 10 mg/kg/day for 3 days, with blood and intracranial tissue samples obtained 2 hours following the third administration. Plasma is separated from whole blood, and frozen at −80°C. After brain resection, tumor tissue is immediately dissected from tumor-bearing hemisphere, then snap frozen and stored at −80°C, as is contralateral hemisphere without tumor. NT113 is extracted from homogenized tissues using a Bullet Blender. Homogenates are extracted with organic solvent and further processed prior to transfer to an autosampler for high performance liquid chromatography (HPLC) analysis, and determination of NT113 content. |
References |
No Any Chemical & Physical Properties |